Featured Research

from universities, journals, and other organizations

Advances in kidney cancer management

Date:
April 19, 2010
Source:
European Association of Urology
Summary:
Renal cell carcinoma accounts for about 3 percent of all solid tumors in adults, and worldwide, more than 200,000 new cases and 100,000 deaths result each year from this malignancy.

Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

"In contrast to most other malignant tumours in the urogenital system, there was a period of stagnation in the development of new treatment modalities for many decades. Surgery in an early stage always was and still is the only measure to cure RCC, and surgery plays an important role in the treatment of metastases as long as they can be removed completely," said Prof. Gόnter Janetschek, one of the speakers at the Plenary Session, Advances in Renal Cell Carcinoma Management.

He added that in contrast, the main targets for other malignancies -- chemotherapy and radiotherapy -- failed to a great extent, and immunotherapy proved to have limited efficacy despite many efforts.

Frequently, the so far standard surgical treatment -- radical nephrectomy -- is an overtreatment for these small tumours, and in addition to partial nephrectomy -- open or laparoscopic -- minimally invasive ablative techniques, namely cryotherapy and radiofrequency, have become an important addition to the range of options available.

Janetschek said a major breakthrough could be achieved in the treatment of advanced disease due to better understanding of tumour biology in general and especially RCC biology. Angiogenesis plays a major role in the growth of malignant tumours, and several substances could be developed to block key proteins involved in angiogenesis and tumour proliferation.

The main strategies target either directly the vascular endothelial growth factor (VEGF), its related receptor or the mammalian target of rapamycin (mTOR) signal transduction pathway.

"Since all of these concepts are new, only limited experience exists so far with their clinical use. However, this experience is growing quickly with each year. Therefore, continuous close communication between all groups working in this field is of outmost importance at this stage," said Janetschek.

VEGF is the most prominent regulator of angiogenesis. Bevacizumab is a monoclonal antibody against VEGF that binds and neutralises all biologic active isoformes of VEGF. Bevacizumab is one of the drugs used as first-line therapy, and there is consensus that the combination of bevacizumab and interferon-alpha is most efficient.

Sunitinib is a highly potent selective inhibitor of multiple tyrosine kinases of the VEGF and PDGF (platelet derived growth factor) receptors. In addition to inhibition of angiogenesis it has direct antiproliferative effects. Sunitinib is recommended as first-line therapy for intermediate- or low-risk patients. Many studies have shown its efficacy.

Sorafenib is a tyrosine kinase inhibitor which inhibits not only the VEGF/PDGF receptors, but also the enzyme RAF (rapidly growing fibrosarcoma) kinase, a critical component of the RAF signaling pathway that controls cell division and proliferation. Sorafenib is advised as second-line therapy. Treatment of cytokine-refractory mRCC patients with sorafenib has been reported to double the progression free survival (PFS) compared with placebo.

Initially, mTOR inhibitors were used as an immunosuppressant to prevent rejection of organ transplants. Temsirolimus is a specific inhibitor of mTOR and interferes with the synthesis of proteins that regulate proliferation, growth, and survival of tumour cells. Treatment with temsirolimus leads to cell cycle arrest in the G1 phase, and also inhibits tumour angiogenesis by reducing synthesis of VEGF.

Temsirolimus is indicated as first-line therapy in high risk patients. It is administered intravenously. Everolimus, which is given orally, has shown in a phase III study to be effective in patients relapsing after initial therapy with tyrosine kinase inhibitors.

None of these drugs cure the patients, but they are able to stabilise mRCC for a certain period of time. Many questions remain open, however. Obviously, there is no cross-resistance in between these drugs, and they can be administered sequentially.

Janetschek said that specialists have to define which the best sequence is in the given patient. Another new approach is the combination of drugs. This approach will result in new side effects which, according to Janetschek urologists have to recognise and manage.


Story Source:

The above story is based on materials provided by European Association of Urology. Note: Materials may be edited for content and length.


Cite This Page:

European Association of Urology. "Advances in kidney cancer management." ScienceDaily. ScienceDaily, 19 April 2010. <www.sciencedaily.com/releases/2010/04/100419090950.htm>.
European Association of Urology. (2010, April 19). Advances in kidney cancer management. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/04/100419090950.htm
European Association of Urology. "Advances in kidney cancer management." ScienceDaily. www.sciencedaily.com/releases/2010/04/100419090950.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins